Artios in-licenses MD Anderson-Shangpharma’s ART inhibitor programme

DNA damage response (DDR)-focused company Artios has in-licensed University of Texas MD Anderson and ShangPharma Innovation’s joint ATR inhibitor programme. As a result, Artios will have exclusive rights to research, development, manufacture and commercialise all products globally – the company expects to submit an investigational new drug application for the lead product in the second half of 2020. Financial terms of the agreement were not disclosed. Artios CEO Dr Niall Martin said: “This programme has the potential to be a highly effective DDR-targeted treatment in cancer. “We look forward to advancing the work done by MD Anderson and ShangPharma for the benefit of cancer patients.” MD Anderson vice-president of the therapeutics discovery team Philip Jones added: “Targeting DNA damage repair has the potential to provide an important therapeutic option for many patients in need of new treatments. “We are pleased Artios will leverage its unique expertise in this field to advance this novel therapy toward the clinic to improve outcomes for cancer patients.” ShangPharma CEO Walter Moos continued: “We are pleased to transition this important programme to the capable development team at Artios, and we hope this ultimately provides an impactful therapy for those afflicted with cancer.”